RxDoctor Payments Data

Masroor Abro, MD

Internal Medicine · Lima, OHNPI 1841528775

Payments from drug & device makers

$10,332in general payments, 2019–2025

Across 210 payments — averaging $49.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Medtronic$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$320
  • Amgen$284
  • E.r. Squibb & Sons, L.L.C.$274
  • Johnson & Johnson$259
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$5,75156%
  • Food & beverage$4,50444%
  • Education$771%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,332 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$280,660
Medicare patients
1,169
Services billed
5,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban564$672,881
Repatha SureclickEvolocumab127$174,753
XareltoRivaroxaban79$106,291
FarxigaDapagliflozin Propanediol126$95,031
EntrestoSacubitril/Valsartan79$90,153
BrilintaTicagrelor61$62,597
Praluent PenAlirocumab40$57,377
Ranolazine ErRanolazine266$26,095
VascepaIcosapent Ethyl26$20,049
Nebivolol Hcl229$12,374
Metoprolol Succinate832$9,284
Midodrine Hcl152$9,162
Isosorbide Mononitrate ErIsosorbide Mononitrate886$9,158
Flecainide Acetate188$8,042
Prasugrel Hcl75$6,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$672,881564 claims
AstraZenecaFarxiga, Brilinta$218$157,628187 claims
Johnson & JohnsonXarelto$259$106,29179 claims
NovartisEntresto$175$90,15379 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →